Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose methylprednisolone and rituximab in previously treated high-risk chronic B-cell lymphocytic leukemia
2007-001818-16Phase 2Completed
- Sponsor
- Vilnius University Hospital Santaros Klinikos
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylprednisolone and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Vilnius University Hospital Santaros Klinikos. Primary endpoint: Efficacy and safety in investigative population. Started May 2007; status: completed.
02
Drugs
methylprednisolonerituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-001818-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001818-16.